F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.

Kylonova (Xiamen) Biopharma Co., Ltd. is mainly engaged in the research and development of new drugs and delivery platforms for siRNA (small interfering nucleic acids). The company has established three delivery platforms for siRNA with proprietary technologies, including Nano-Lipid Particle(NPDP) , a Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards of three delivery platforms are on the cutting-edge in the same fields, and can be scaled-up and manufactured for commercialization. Kylonova also performssolid phase oligonucleotide synthesis and DNA and RNA API production and can supply a contract manufacture.

Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' product pipeline represents candidates indicated for the treatment of metabolic diseases such as hyperlipidemia and diabetes, among others. Additionally, our pipeline includes drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer which the company plans to license to companies focused on these areas. All of our product candidates were developed internally using proprietary technologies including our NuMimetic and HepDirect technologies.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Sunshine Lake Pharma Co. Ltd., a subsidiary of Shenzhen Dongyangguang Industry Co., Ltd., is a Chinese company. The firm manufactures and supplies pharmaceutical ingredients and drugs. Wen Jia Li has been the CEO since 2021. On December 23, 2022 Shenzhen Dongyangguang Industry Co., Ltd. acquired Sunshine Lake Pharma Co. Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd. for $330.99 million.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets. Based in San Mateo, California and Shanghai, Terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in China and globally.

Sichuan Haisco Pharmaceutical Co., Ltd., established on 2003-09-29, Business scope includes licensed projects:pharmaceutical production;Drug import and export;Pharmaceutical commissioned production;Drug retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. Its products include original medicine such as Chidamide, Chiglitazar, Chiauranib. It also engages in technological licensing. The company was founded by Xian Ping Lu and Zhi Qiang Ning on March 21, 2001 and is headquartered in Shenzhen, China.

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of pharmaceutical products and health foods. It operates through the following segments: Pharmaceuticals, Information Service, and Others. The Pharmaceuticals segment researches, develops, manufactures, and markets drugs, which are used in the fields of urology, dialysis, women's health, ophthalmology, endocrinology and metabolism. The Information Service segment offers information services to use in IT and capital investment. The Others segment includes merchandise sales and construction contractors. The company was founded on August 9, 1946 and is headquartered in Matsumoto, Japan.

Nanjing Ruijie Pharmaceutical Technology Co., Ltd., established on 2014-06-04, Business scope includes biological,pharmaceutical products,Research and development of health products;Chemical raw materials,Pharmaceutical Intermediates,cosmetic,Packaging Materials,laboratory consumables,Instrumentation,Electronic product development,Sales and technology transfer,technical consulting,Technical Services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)(The proportion of foreign capital is lower than25%) licensed items:pharmaceutical production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Pharmaceutical commissioned production;Drug retail;Drug Wholesale(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Manufactures and supplies laser processing systems, oscillators and machines

Fronthera U.S. Pharmaceuticals LLC, a subsidiary of Haisco Pharmaceutical Group Co., Ltd., is an American company located in San Diego, CA. The firm engages in drug discovery and development.

Case Kaidi (Shanghai) Pharmaceutical Technology Co., Ltd., established on 2017-12-26, Business scope includes pharmaceutical,Research and development of pharmaceutical intermediates,Transfer of self-owned R&D results,And provide relevant technical advice and technical services,medicine,chemical product(Hazardous Chemicals,Civilian Explosives Excluded)Wholesale,import and export,commission agent(except auction),and provide related services(Commodities that do not involve state trade management,Quota involved,of license-managed goods,Apply in accordance with relevant national regulations).[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Case Kaixu (Shanghai) Pharmaceutical Technology Co., Ltd., established on 2020-07-06, Business scope includes general items:Medical Technology(human stem cells,Except for the development and application of genetic diagnosis and treatment technology)technology development in the field,technical consulting,technology transfer,Technical Services,Technology Promotion;business management;Information Consulting Service(Not including licensing information consulting services)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).